21
Participants
Start Date
December 21, 2023
Primary Completion Date
August 27, 2024
Study Completion Date
August 27, 2024
VH3739937
VH3739937 will be administered.
Placebo
Placebo will be administered.
GSK Investigational Site, Vitoria-Gasteiz
GSK Investigational Site, Rosario
GSK Investigational Site, Jerez de la Frontera
GSK Investigational Site, Athens
GSK Investigational Site, A Coruña
GSK Investigational Site, Genova
GSK Investigational Site, Granada
GSK Investigational Site, Milan
GSK Investigational Site, Brescia
GSK Investigational Site, Madrid
GSK Investigational Site, Madrid
GSK Investigational Site, Miami
GSK Investigational Site, Dallas
GSK Investigational Site, Bakersfield
GSK Investigational Site, Buenos Aires
GSK Investigational Site, Roma
GSK Investigational Site, Warsaw
GSK Investigational Site, Alicante
Lead Sponsor
ViiV Healthcare
INDUSTRY